Edoxaban tosylate monohydrate

产品说明书

Print
Chemical Structure| 1229194-11-9 同义名 : 依度沙班对甲苯磺酸盐一水化合物 ;DU-176b monohydrate; DU-176b
CAS号 : 1229194-11-9
货号 : A100306
分子式 : C31H40ClN7O8S2
纯度 : 98+%
分子量 : 738.27
MDL号 : MFCD28400751
存储条件:

Pure form Inert atmosphere, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(67.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 1 mg/mL(1.35 mM),配合低频超声助溶

生物活性
靶点
  • Factor Xa

    Factor Xa, Ki:0.561 nM

描述 Factor Xa (FXa) is a coagulation factor thrombokinase responsible for the generation of thrombin. Edoxaban Tosylate Monohydrate is the tosylate monohydrate form of Edoxaban. Edoxaban is a direct, selective FXa inhibitor with a Ki value of 0.561nM. In uman plasma samples, the minimum concentrations of edoxaban needed to significantly prolong prothrombin time (PT) and activated partial thromboplastin time were 55 and 50ng/mL, respectively. Plasma edoxaban at the concentration of 5.5 – 1640 ng/ml inhibited the generation of thrombin in a dose-dependent manner. Edoxaban above 10 ng/ml significantly extended the initiation phase of thrombin generation. In human platelet-poor plasma, the peak IC50 value, mRate IC50 value, and endogenous thrombin potential (ETP) IC50 value measured in thrombin generation assay were 0.145, 0.047, and 1.39 µM, respectively. The doses of edoxaban required to reach 50% of inhibition of CT2 lag time and ttPeak were 0.188 and 0.139 µM, respectively. In human platelet-rich plasma, the peak IC50, mRate IC50, and ETP IC50 values were 0.305, 0.230, and 0.636 µM, respectively. In apolipoprotein E (ApoE)-deficient mice, the treatment with 15 mg/kg edoxaban one hour before vascular injury almost completely prevented thrombus formation, and significantly decreased the time to occlusion and the patency rate. The following chronic oral administration of 10 mg/kg edoxaban by gavage b.i.d for six weeks significantly suppressed neointimal hyperplasia.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.35mL

0.27mL

0.14mL

6.77mL

1.35mL

0.68mL

13.55mL

2.71mL

1.35mL

参考文献

[1]Mendell J, Noveck RJ, Shi M. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination. J Cardiovasc Pharmacol. 2012 Oct;60(4):335-41.

[2]Furugohri T, Isobe K, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008 Sep;6(9):1542-9.

[3]DU-176b